文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

COVID-19重症患者巨细胞病毒血症再激活:危险因素及对死亡率的影响

Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality.
PubMed 文献 · Intensive Care Med · 2022-05-18
一句话结论COVID-19 ICU患者CMV血症再激活率20.4%,病情严重度和继发细菌感染增加再激活风险,但调整后未证实其独立影响死亡率。

本研究为观察性研究,纳入2020年2月至2021年7月三家ICU连续收治的431例确诊SARS-CoV-2感染合并急性呼吸窘迫综合征患者,入ICU时及每周1—2次定量检测血CMV-DNA。结果88例(20.4%)出现CMV血症再激活,SAPS II评分、血小板计数、有创机械通气及ICU期间继发细菌感染与再激活相关。再激活组住院死亡率67.0%,无再激活组24.5%,但调整后分析未证实该关联(HR 1141,95%CI 0.757-1721,p=0.528)。结论认为病情严重度和继发细菌感染增加CMV再激活风险,但再激活似乎不独立影响COVID-19 ICU患者结局。

要点

  • 431例COVID-19合并ARDS的ICU患者中88例(20.4%)出现CMV血症再激活。
  • 再激活组住院死亡率67.0%,无再激活组24.5%,但调整后HR 1141(95%CI 0.757-1721,p=0.528)未证实独立关联。
  • SAPS II评分(HR 1031,95%CI 1010-1053,p=0.006)与CMV再激活相关。
  • 有创机械通气(HR 2611,95%CI 1223-5571,p=0.013)及继发细菌感染(HR 5041,95%CI 2852-8911,p<0.0001)与CMV再激活相关。
  • 血小板计数(HR 0.0996,95%CI 0.993-0.999,p=0.004)与CMV再激活相关。

适用人群与场景

  • 2020年2月至2021年7月三家ICU连续收治的确诊SARS-CoV-2感染合并急性呼吸窘迫综合征患者,共431例。

处置流程与药物剂量

  • 入ICU时及之后每周1—2次定量检测血CMV-DNA。

研究设计与关键结果

  • 观察性研究,纳入431例COVID-19合并ARDS的ICU患者,88例(20.4%)出现CMV血症再激活。
  • SAPS II评分(HR 1031,95%CI 1010-1053,p=0.006)、血小板计数(HR 0.0996,95%CI 0.993-0.999,p=0.004)、有创机械通气(HR 2611,95%CI 1223-5571,p=0.013)及ICU期间继发细菌感染(HR 5041,95%CI 2852-8911,p<0.0001)与CMV再激活相关。
  • 再激活组住院死亡率67.0%,无再激活组24.5%,但调整后分析未证实关联(HR 1141,95%CI 0.757-1721,p=0.528)。

证据类型、等级与局限

  • 观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,病情严重度和继发细菌感染与CMV血症再激活风险增加相关,但再激活似乎不独立影响COVID-19 ICU患者结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Cytomegalovirus (CMV) reactivation in immunocompetent critically ill patients is common and relates to a worsening outcome. In this large observational study, we evaluated the incidence and the risk factors associated with CMV reactivation and its effects on mortality in a large cohort of patients affected by coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU).

METHODS: Consecutive patients with confirmed SARS-CoV-2 infection and acute respiratory distress syndrome admitted to three ICUs from February 2020 to July 2021 were included. The patients were screened at ICU admission and once or twice per week for quantitative CMV-DNAemia in the blood. The risk factors associated with CMV blood reactivation and its association with mortality were estimated by adjusted Cox proportional hazards regression models.

RESULTS: CMV blood reactivation was observed in 88 patients (20.4%) of the 431 patients studied. Simplified Acute Physiology Score (SAPS) II score (HR 1031, 95% CI 1010-1053, p = 0.006), platelet count (HR 0.0996, 95% CI 0.993-0.999, p = 0.004), invasive mechanical ventilation (HR 2611, 95% CI 1223-5571, p = 0.013) and secondary bacterial infection (HR 5041; 95% CI 2852-8911, p < 0.0001) during ICU stay were related to CMV reactivation. Hospital mortality was higher in patients with (67.0%) than in patients without (24.5%) CMV reactivation but the adjusted analysis did not confirm this association (HR 1141, 95% CI 0.757-1721, p = 0.528).

CONCLUSION: The severity of illness and the occurrence of secondary bacterial infections were associated with an increased risk of CMV blood reactivation, which, however, does not seem to influence the outcome of COVID-19 ICU patients independently.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gatto I, Biagioni E, Coloretti I, et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med. 2022. PMID: 35583676. doi:10.1007/s00134-022-06716-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。